⌕
Immix Biopharma · IMMX · Nasdaq
Tenet 69 · Solid
Compare
$7.48−4.59%At closeTenet 69 · Solid
$7.48−0.36 (−4.59%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Immix Biopharma (IMMX) Key Ratios

Valuation, quality, health and growth. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.

Sources Company filings and market prices Filings and pricesRatios computed How we compute thisNot investment advice
79
VALUE
Low multiples vs sector
discount to its peers
36
QUALITY
Weak
below-peer returns
90
HEALTH
Sturdy
conservative balance sheet
—
GROWTH
No data
no inputs scored

A weak business at low multiples for its sector: value 79, quality 36, health 90, each a percentile within Healthcare.

Values are the trailing twelve months where a company files quarterly statements and the figure passes our check against the filings, with balance-sheet ratios from the most recent quarter; otherwise, or where a sector's figure is still under review, the latest fiscal year. Piotroski and the five-year growth rates are fiscal years. Each row names its period.track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own ten fiscal years (context, not scored)hover any metric for its formula
79th pctilediscount to its peers
Earnings yield (EBIT/EV)EBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.—Not meaningful: operating income is zero or negative.
P/E—Not meaningful: the company made a loss.
P/B2.079th pctileMarket cap at the close of Nov 13, 2026 ÷ book equity at Sep 30, 2026 (most recent quarter)
P/FCF—Not meaningful: the denominator is zero or negative.
EV / EBITDA—Not meaningful: EBITDA is zero or negative.
90th pctileconservative balance sheet
Current ratio33.7298th pctileMost recent quarter, Sep 30, 2026
Quick ratioMost recent quarter: (Cash, short-term investments and receivables) ÷ current liabilities on the most recent quarter's balance sheet, as the data vendor builds it for that quarter. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.33.5598th pctileMost recent quarter, Sep 30, 2026
Net debt / EBITDA(Total debt − cash) ÷ EBITDA—Not meaningful: EBITDA is zero or negative.
Interest coverage—Not meaningful: operating income is zero or negative.
Debt / equity0.0074th pctileown record too shortMost recent quarter, Sep 30, 2026
36th pctilebelow-peer returns
ROIC−15%41st pctileown record too shortTTM through Sep 30, 2026
ROE−27%38th pctileTTM through Sep 30, 2026
Gross margin—Not reported in the company's filings for this period.
Net margin—Not reported in the company's filings for this period.
Income quality (CFO/NI)—Not meaningful: the company made a loss.
Piotroski F3 / 930th pctileown record too shortFiscal 2025 (Dec 31, 2025)
Altman Z—Not reported in the company's filings for this period.
no inputs scored
Revenue CAGRThe yearly rate that compounds the earliest fiscal year's revenue into the latest one, over the true number of fiscal years between them (up to five). When the earliest year's revenue is zero or negative, the rate starts from the first later year with at least $10M of revenue, provided at least three years remain.—This growth figure starts in a period outside the history your plan includes.
EPS CAGR—This growth figure starts in a period outside the history your plan includes.
FCF margin—Not reported in the company's filings for this period.
the receipts behind the numbers above
Greenblatt earnings yield—EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC−15%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage— Guarded, not faked: we have no interest-expense figure on file for this company, so it's excluded from the ranking instead of rendered as garbage.
Percentiles computed nightly against 409 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value (the trailing twelve months or the latest fiscal year, as its row names) sits in the company's own ten fiscal-year record, shown for context and never blended into the score. Computed Nov 16, 2026 · Not investment advice.

What is Immix Biopharma's Piotroski F-Score?

Immix Biopharma's Piotroski F-Score is 3 of 9 for fiscal 2025.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.